MAGE-C2–Specific TCRs Combined with Epigenetic Drug-Enhanced Antigenicity Yield Robust and Tumor-Selective T Cell Responses

Take two: Combining immunotherapy with epigenetic drugs to tackle cancer

(2016) Karen Weintraub   NATURE MEDICINE

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

(2015) Katherine B. Chiappinelli et al.   CELL

Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor

(2015) Joost H van den Berg et al.   MOLECULAR THERAPY

Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy

(2015) Dongjun Peng et al.   NATURE

Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice

(2015) Matthias Obenaus et al.   NATURE BIOTECHNOLOGY

NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma

(2015) Aaron P Rapoport et al.   NATURE MEDICINE

Epigenetics Meets Immune Checkpoints

(2015) Alessia Covre et al.   SEMINARS IN ONCOLOGY

Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome

(2015)   Oncotarget

MAGEC2, an epithelial-mesenchymal transition inducer, is associated with breast cancer metastasis

(2014) Fan Yang et al.   BREAST CANCER RESEARCH AND TREATMENT

A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

(2014) P. F. Robbins et al.   CLINICAL CANCER RESEARCH

Vaccination of a Melanoma Patient with Mature Dendritic Cells Pulsed with MAGE-3 Peptides Triggers the Activity of Nonvaccine Anti-Tumor Cells

(2014) J. Carrasco et al.   JOURNAL OF IMMUNOLOGY

TCRs Genetically Linked to CD28 and CD3ε Do Not Mispair with Endogenous TCR Chains and Mediate Enhanced T Cell Persistence and Anti-Melanoma Activity

(2014) Coen Govers et al.   JOURNAL OF IMMUNOLOGY

Differential Antigen Expression Profile Predicts Immunoreactive Subset of Advanced Ovarian Cancers

(2014) Kevin H. Eng et al.   PLoS One

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma

(2013) G. P. Linette et al.   BLOOD

Relapse or Eradication of Cancer Is Predicted by Peptide-Major Histocompatibility Complex Affinity

(2013) Boris Engels et al.   CANCER CELL

SHP-1 phosphatase activity counteracts increased T cell receptor affinity

(2013) Michael Hebeisen et al.   JOURNAL OF CLINICAL INVESTIGATION

Interplay between T Cell Receptor Binding Kinetics and the Level of Cognate Peptide Presented by Major Histocompatibility Complexes Governs CD8+T Cell Responsiveness

(2012) Melita Irving et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Analysis of the Processing of Seven Human Tumor Antigens by Intermediate Proteasomes

(2012) B. Guillaume et al.   JOURNAL OF IMMUNOLOGY

Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen

(2011) S. Thomas et al.   BLOOD

Inhibition of Histone Lysine Methylation Enhances Cancer-Testis Antigen Expression in Lung Cancer Cells: Implications for Adoptive Immunotherapy of Cancer

(2011) M. Rao et al.   CANCER RESEARCH

Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4

(2011) C. R. Cruz et al.   CLINICAL CANCER RESEARCH

A MAGE-C2 antigenic peptide processed by the immunoproteasome is recognized by cytolytic T cells isolated from a melanoma patient after successful immunotherapy

(2011) Wenbin Ma et al.   INTERNATIONAL JOURNAL OF CANCER

Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

(2011) Paul F. Robbins et al.   JOURNAL OF CLINICAL ONCOLOGY

Expression of MAGE-C1/CT7 and MAGE-C2/CT10 Predicts Lymph Node Metastasis in Melanoma Patients

(2011) Alessandra Curioni-Fontecedro et al.   PLoS One

Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid

(2011) Andrea Kuendgen et al.   Clinical Epigenetics

Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia

(2010) O. Goodyear et al.   BLOOD

High expression of cancer testis antigens MAGE-A, MAGE-C1/CT7, MAGE-C2/CT10, NY-ESO-1, and gage in advanced squamous cell carcinoma of the larynx

(2010) David L. A. Figueiredo et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma

(2010) Cyril Cuffel et al.   INTERNATIONAL JOURNAL OF CANCER

A TCR Targeting the HLA-A*0201-Restricted Epitope of MAGE-A3 Recognizes Multiple Epitopes of the MAGE-A Antigen Superfamily in Several Types of Cancer

(2010) N. Chinnasamy et al.   JOURNAL OF IMMUNOLOGY

Modification of MHC Anchor Residues Generates Heteroclitic Peptides That Alter TCR Binding and T Cell Recognition

(2010) D. K. Cole et al.   JOURNAL OF IMMUNOLOGY

Evidence for a TCR Affinity Threshold Delimiting Maximal CD8 T Cell Function

(2010) D. A. Schmid et al.   JOURNAL OF IMMUNOLOGY

T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis

(2010) Maria R Parkhurst et al.   MOLECULAR THERAPY

T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing

(2010) Coen Govers et al.   TRENDS IN MOLECULAR MEDICINE

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

(2009) L. A. Johnson et al.   BLOOD

Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes

(2009) M. T. Voso et al.   CLINICAL CANCER RESEARCH

Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression

(2008) Jennifer A. Wargo et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Phase I Study of Epigenetic Modulation with 5-Azacytidine and Valproic Acid in Patients with Advanced Cancers

(2008) F. Braiteh et al.   CLINICAL CANCER RESEARCH

Genome-wide analysis of cancer/testis gene expression

(2008) O. Hofmann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA